Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

This study aims to evaluate whether maintenance therapy with decitabine, venetoclax and blinatumomab could improve the 2-year progression free survival (PFS) of patients with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who had recently received an allogeneic stem cell transplant and in measurable residual disease-negative remission.

Trial Details

NCT ID

NCT06393985

Phase

PHASE2

Sponsor

The First Affiliated Hospital of Soochow University

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Decitabine, venetoclax and blinatumomab

Locations (sample)

Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent an alloHSCT as follows:
patients in CR1 with high-risk features,including adverse clinical features, cytogenetic or molecular alterations according to NCCN 2023.V3.
patients lack of achievement of complete remission after standard induction chemotherapy.
patients with detectable minimal residual disease pre-transplantation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →